Scientific Reports (Jun 2023)

Utility of a rapid assay for prostaglandin E-major urinary metabolite as a biomarker in pediatric ulcerative colitis

  • Shin-ichiro Hagiwara,
  • Naoki Abe,
  • Kenji Hosoi,
  • Tomoko Hara,
  • Takashi Ishige,
  • Hirotaka Shimizu,
  • Tatsuki Mizuochi,
  • Toshihiko Kakiuchi,
  • Reiko Kunisaki,
  • Ryo Matsuoka,
  • Hiroki Kondou,
  • Fumihiko Kakuta,
  • Yoshiko Nakayama,
  • Takeshi Kimura,
  • Takatoshi Maeyama,
  • Hitoshi Honma,
  • Daishi Hirano,
  • Masayuki Saruta,
  • Tsutomu Yoshida,
  • Isao Okayasu,
  • Yuri Etani

DOI
https://doi.org/10.1038/s41598-023-37145-6
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Prostaglandin E-major urinary metabolite (PGE-MUM) is a urinary biomarker reflecting ulcerative colitis (UC) activity. This prospective observational study aimed to evaluate the usefulness of PGE-MUM via rapid chemiluminescent enzyme immunoassay in detecting endoscopic remission (ER) and histologic remission (HR) in pediatric UC (6–16 years) in comparison with fecal calprotectin (FCP). ER and HR were defined as Mayo endoscopic score (MES) of 0 and Matts’ histological grades (Matts) of 1 or 2, respectively. A total of 104 UC and 39 functional gastrointestinal disorder (FGID) were analyzed. PGE-MUM levels were significantly higher in the UC group than in the FGID group (P < 0.001). FCP levels were significantly elevated in the group without ER and HR than in the group with ER and HR (P < 0.001 and P = 0.001), whereas PGE-MUM levels were significantly higher in the group without ER compared to the group with ER (P < 0.001). No significant differences were noted in the AUCs for PGE-MUM and FCP in detecting ER and HR. Although PGE-MUM was inferior to FCP for the detection of HR, it might have the potential for application as a biomarker of endoscopic activity in pediatric UC owing to its noninvasive and rapid method.